Issue: July 25, 2017
June 22, 2017
2 min read
Save

Two iStent injects and topical travoprost reduce IOP, medication use through 18 months

Issue: July 25, 2017
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The implantation of two second-generation iStent inject devices and postoperative topical prostaglandin in eyes with open-angle glaucoma reduced mean IOP and medication use at 18 months, according to a study.

Perspective from Nathan Radcliffe, MD

The prospective, nonrandomized, open-label study included 53 patients with open-angle glaucoma and preoperative IOP of 18 mm Hg to 30 mm Hg on two medications; IOP ranged from 22 mg to 38 mm Hg after medication washout. The patients were implanted with two iStent inject devices (Glaukos) and received postoperative topical travoprost. Patients were followed for 18 months, and medication washout was repeated at month 12.

The primary outcome of the study was a reduction of IOP by 20% compared with medicated baseline IOP and a reduction of at least one medication at 12 months.

At 1 year, IOP was reduced by 20% or more in 91% of eyes with a reduction of one medication. Also, 100% of eyes had an IOP of 18 mm Hg or less with a reduction of one medication and 87% had IOP of 15 mm Hg or less.

The mean medicated IOP for all patients through 18 months was 12.9 mm Hg, or a 37% reduction from the preoperative baseline. No adverse events were observed in the 18-month study. – by Robert Linnehan

Disclosure: Berdahl reports he received financial support from Glaukos for his work as an investigator in this study. Please see the study for all other authors’ relevant financial disclosures